UCB Inc.

Smyrna, GA, United States
Smyrna, GA, United States
Time filter
Source Type

Rubin Z.A.,Emory University | Ault K.A.,UCB Inc.
Clinical Obstetrics and Gynecology | Year: 2013

Social networking sites are a popular way for physicians to communicate about clinical, professional, and social topics. These sites can be used for educational purposes, professional interaction, and for general discussion. There are many popular sites oriented toward health care professionals, each with their own functionality and style. We reviewed the top physician-oriented networking sites, as well as popular general social networking sites that can be used for physician communication. We also provide background on social media communication, as well as specific advice for online physician communication and a discussion of confidentiality. © 2013, Lippincott Williams & Wilkins.

Wicks P.,PatientsLikeMe Inc. | Keininger D.L.,UCB Pharma | Massagli M.P.,PatientsLikeMe Inc. | la Loge C.D.,UCB Pharma | And 3 more authors.
Epilepsy and Behavior | Year: 2012

An epilepsy community was developed on PatientsLikeMe.com to share data between patients to improve their outcomes by finding other patients like them. In a 14-day response period, 221 patients with epilepsy (mean age: 40. years, SD: 12, range: 17-72, 66% female) completed a survey about benefits they perceived. Prior to using the site, a third of respondents (30%) did not know anyone else with epilepsy with whom they could talk; of these, 63% now had at least one other patient with whom they could connect. Perceived benefits included: finding another patient experiencing the same symptoms (59%), gaining a better understanding of seizures (58%), and learning more about symptoms or treatments (55%). Number of benefits was associated with number of relationships with other patients, F(4,216) = 8.173, P< 0.001). Patients with epilepsy reported an array of perceived benefits similar to those reported by populations with other diseases. Controlled sharing of health data may have the potential to improve disease self-management of people with epilepsy. © 2011 Elsevier Inc.

Krauss G.,Johns Hopkins Hospital | Ben-Menachem E.,Sahlgrenska University Hospital | Mameniskiene R.,Vilnius University | Vaiciene-Magistris N.,Kaunas Medical University Hospital | And 3 more authors.
Epilepsia | Year: 2010

Purpose: Lacosamide is a new antiepileptic drug effective for adjunctive treatment of partial-onset seizures. We evaluated the safety and tolerability of an intravenous (i.v.) formulation of lacosamide (200-800 mg/day) infused over 10, 15, and 30 min as short-term replacement for oral lacosamide in patients with partial-onset seizures. Methods: This multicenter, open-label, inpatient trial enrolled 160 patients from ongoing open-label, long-term trials who were taking stable doses of oral lacosamide and up to three concomitant antiepileptic drugs (AEDs). Serial cohorts of patients were converted from oral lacosamide treatment to the same intravenous doses infused over progressively shorter infusion durations: 30, 15, and 10 min for 2-5 days. A data monitoring committee (DMC) reviewed safety data for each cohort. The safety of intravenous lacosamide was assessed from adverse events (AEs), laboratory variables, electrocardiography findings, and physical/neurologic examinations. Results: A total of 160 patients received lacosamide 200-800 mg/day, i.v., for 2-5 days, of which 69% received 400-800 mg/day doses. The most common AEs (reported by ≤10% of patients) were headache, dizziness, and somnolence. There was no increase in frequency or severity of AEs with shorter durations of infusion or increased days of exposure. AEs were similar, but more frequent, with higher doses (≥400 mg/day). Injection-site events were rare and did not appear to be linked to infusion doses or rates. Lacosamide plasma concentrations were linearly related to dose across the cohorts. Discussion: This comprehensive evaluation supports the safety of an intravenous lacosamide infusion duration as short as 15 min for short-term (2-5 days) replacement for patients temporarily unable to take oral lacosamide. © 2009 International League Against Epilepsy.

Hampel F.,Central Texas Health Research | Ratner P.,Sylvana Research Associates | Haeusler J.-M.C.,UCB Inc.
Allergy and Asthma Proceedings | Year: 2010

Allergic rhinitis (AR) and chronic idiopathic urticaria (CIU) are common causes of substantial illness and disability in preschool children. Antihistamines are commonly used to treat preschool children with these conditions, but their use is based mostly on extrapolated efficacy from adult populations; it is thus important to characterize the safety of antihistamines in the pediatric population. This study was designed to assess the safety of levocetirizine dihydrochloride oral liquid drops in infants and children with AR or CIU. Two multicenter, double-blind, randomized, parallel-group studies randomized infants aged 6-11 months (study 1, n = 69) and children aged 1-5 years (study 2, n = 173) to levocetirizine, 1.25 mg (q.d. or b.i.d., respectively), or placebo for 2 weeks, using a 2:1 ratio. Safety evaluations included treatment-emergent adverse events (TEAEs), vital signs, electrocardiographic (ECG) assessments, and laboratory tests. The overall incidence of TEAEs was similar between levocetirizine and placebo in both studies. Most TEAEs were mild or moderate in intensity. TEAEs prompted discontinuation of therapy in three patients receiving levocetirizine in study 1. No clinically relevant changes from baseline in vital signs or laboratory parameters were apparent in either study; changes from baseline in these evaluations were similar between groups. No significant changes were observed in ECG parameters, including corrected QT interval. Levocetirizine, 1.25 and 2.5 mg/day, was well tolerated in infants aged 6-11 months and in children aged 1-5 years, respectively, with AR or CIU. Copyright © 2010, OceanSide Publications, Inc.

Curtis J.R.,University of Alabama at Birmingham | Hobar C.,UCB Inc. | Hansbrough K.,UCB Inc.
Current Medical Research and Opinion | Year: 2011

Objective: Some patients with rheumatoid arthritis (RA) who receive injectable biologics experience injection-site burning and stinging (ISBS); however, the prevalence of ISBS in the general RA population is unknown and may impact preference for an injectable biologic. This study assessed the prevalence of ISBS and associated comorbidities in patients with RA who receive injectable biologics. Research design and methods: The physician and patient survey consisted of a retrospective chart review and a prospective assessment. In the former, each participating US rheumatologist reviewed the medical records of five randomly selected RA patients receiving an injectable biologic. In the prospective assessment, each rheumatologist was asked to report data based on interviews with up to 50 RA patients currently treated with an injectable biologic, who were asked whether they had ISBS during or after their most recent injection. Results: Data were analyzed for 504 patients in the retrospective chart review and 3326 patients in the prospective assessment; data were provided by 101 physicians. The overall prevalence of ISBS was 17 and 58 in the retrospective chart review and prospective analyses, respectively. Out of the 1939 prospectively assessed patients who experienced at least some ISBS, 429 (22) rated the level of ISBS as moderate to severe (13 of total). Increased risk of ISBS was associated with female gender, fibromyalgia, depression, and more severe RA. Conclusions: The prevalence of ISBS is likely underestimated in many rheumatology practices. Specifically asking about it may identify patients who experience this side effect, provide a more accurate understanding of how significantly it affects them, and provide an opportunity for intervention in light of their preferences. © 2011 Informa UK Ltd.

Pastuzyn E.D.,University of Utah | Chapman D.E.,University of Utah | Chapman D.E.,UCB Inc. | Wilcox K.S.,University of Utah | Keefe K.A.,University of Utah
Neuropsychopharmacology | Year: 2012

Methamphetamine (METH) causes partial depletion of central monoamine systems and cognitive dysfunction in rats and humans. We have previously shown and now further show that the positive correlation between expression of the immediate-early gene Arc (activity-regulated, cytoskeleton-associated) in the dorsomedial (DM) striatum and learning on a response reversal task is lost in rats with METH-induced striatal dopamine loss, despite normal behavioral performance and unaltered N-methyl-D-aspartate (NMDA) receptor-mediated excitatory post-synaptic currents, suggesting intact excitatory transmission. This discrepancy suggests that METH-pretreated rats may no longer be using the dorsal striatum to solve the reversal task. To test this hypothesis, male Sprague-Dawley rats were pretreated with a neurotoxic regimen of METH or saline. Guide cannulae were surgically implanted bilaterally into the DM striatum. Three weeks after METH treatment, rats were trained on a motor response version of a T-maze task, and then underwent reversal training. Before reversal training, the NMDA receptor antagonist DL-2-amino-5-phosphonopentanoic acid (AP5) or an Arc antisense oligonucleotide was infused into the DM striatum. Acute disruption of DM striatal function by infusion of AP5 impaired reversal learning in saline-, but not METH-, pretreated rats. Likewise, acute disruption of Arc, which is implicated in consolidation of long-term memory, disrupted retention of reversal learning 24 h later in saline-, but not METH-, pretreated rats. These results highlight the critical importance of Arc in the striatum in consolidation of basal ganglia-mediated learning and suggest that long-term toxicity induced by METH alters the cognitive strategies/neural circuits used to solve tasks normally mediated by dorsal striatal function. © 2012 American College of Neuropsychopharmacology. All rights reserved.

Benitez A.,UCB Inc. | Edens H.,UCB Inc. | Fishman J.,UCB Inc. | Moran K.,UCB Inc. | Asgharnejad M.,UCB Inc
Annals of the New York Academy of Sciences | Year: 2014

Rotigotine is a nonergoline dopamine receptor agonist with structural similarity to dopamine. Rotigotine binds to the D1 through D5 dopamine receptors, having several times more affinity than dopamine does to the D2 and D3 receptors. Although rotigotine was demonstrated to restore locomotor activity in animal models of Parkinson's disease (PD), the rapid metabolism of rotigotine limited the development of an orally administered formulation. Rotigotine's high lipid solubility and extended duration of action when applied to the skin in experimental models of PD suggested that rotigotine was a candidate for transdermal application. The constant transdermal delivery of rotigotine over 24 h is hypothesized to approximate continuous agonist-receptor stimulation, which conceptually more closely mimics physiologic striatal dopamine receptor function. Randomized clinical studies have demonstrated rotigotine's efficacy, safety, and tolerability in patients with early- and advanced-stage PD, including improvements in motor symptoms and off-time. Although the etiology is unknown, restless legs syndrome (RLS) is thought to involve dopaminergic dysregulation. Randomized clinical studies also have demonstrated the efficacy of rotigotine in improving the symptoms of moderate-to-severe primary RLS. This review examines rotigotine's developmental history for transdermal administration leading to its approval for the treatment of early- and advanced-stage PD and moderate-to-severe primary RLS. © 2014 The Authors. Annals of the New York Academy of Sciences published by Wiley Periodicals Inc. on behalf of The New York Academy of Sciences.

Begley C.E.,University of Texas Health Science Center at Houston | Durgin T.L.,UCB Inc.
Epilepsia | Year: 2015

Summary Objective To develop estimates of the direct cost of epilepsy in the United States for the general epilepsy population and sub-populations by systematically comparing similarities and differences in types of estimates and estimation methods from recently published studies. Methods Papers published since 1995 were identified by systematic literature search. Information on types of estimates, study designs, data sources, types of epilepsy, and estimation methods was extracted from each study. Annual per person cost estimates from methodologically similar studies were identified, converted to 2013 U.S. dollars, and compared. Results From 4,104 publications discovered in the literature search, 21 were selected for review. Three were added that were published after the search. Eighteen were identified that reported estimates of average annual direct costs for the general epilepsy population in the United States. For general epilepsy populations (comprising all clinically defined subgroups), total direct healthcare costs per person ranged from $10,192 to $47,862 and epilepsy-specific costs ranged from $1,022 to $19,749. Four recent studies using claims data from large general populations yielded relatively similar epilepsy-specific annual cost estimates ranging from $8,412 to $11,354. Although more difficult to compare, studies examining direct cost differences for epilepsy sub-populations indicated a consistent pattern of markedly higher costs for those with uncontrolled or refractory epilepsy, and for those with comorbidities. Significance This systematic review found that various approaches have been used to estimate the direct costs of epilepsy in the United States. However, recent studies using large claims databases and similar methods allow estimation of the direct cost burden of epilepsy for the general disease population, and show that it is greater for some patient subgroups. Additional research is needed to further understand the broader economic burden of epilepsy and how it varies across subpopulations. © Wiley Periodicals, Inc. © 2015 International League Against Epilepsy.

de la Loge C.,UCB SA | Hunter S.J.,University of Chicago | Schiemann J.,UCB Inc. | Yang H.,Formerly UCB Inc.
Epilepsy and Behavior | Year: 2010

A randomized, double-blind, placebo-controlled study (N01103, NCT00105040) evaluated behavioral and emotional effects of adjunctive levetiracetam (LEV) treatment in children and adolescents (4-16. years old) with uncontrolled partial-onset seizures. Patients received adjunctive LEV 20-60. mg/kg/day (n=64) or placebo (n=34) for 12. weeks. The Achenbach Child Behavior Checklist (CBCL) and portions of the Child Health Questionnaire-Parent Form 50 (CHQ-PF50) were used to assess behavioral and emotional functioning at baseline and end of the treatment period. Worsening of the mean CBCL Aggressive Behavior score occurred for LEV but not placebo, leading to similar results for Externalizing Syndromes and Total Problems (all P<0.05 vs placebo). The change in the CBCL Activities Competence score favored LEV (P<0.05). These results are in line with the known safety profile of LEV. © 2010 Elsevier Inc.

UCB Inc. | Date: 2013-07-02

Analgesics; Oral analgesics; Oral analgesics in solution or liquid form; Analgesic preparations; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally.

Loading UCB Inc. collaborators
Loading UCB Inc. collaborators